Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer

Klaus Mross,Annette Frost,M. E. Scheulen,Jürgen Krauss,Dirk Strumberg,Beate Schultheiss,Ulrike Fasol,Martin Büchert,Jörn Krätzschmer,Heinz Delesen,Prabhu Rajagopalan,Olaf Christensen

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer

2011

Klaus Mross
Annette Frost
M. E. Scheulen
Jürgen Krauss
Dirk Strumberg
Beate Schultheiss
Ulrike Fasol
Martin Büchert
Jörn Krätzschmer
Heinz Delesen
Prabhu Rajagopalan
Olaf Christensen

Background Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases.

Keywords:

Immunology
Medicine
Colorectal cancer
Vascular endothelial growth factor
Biomarker (medicine)
Tyrosine kinase
Cancer research
Sunitinib
Pharmacokinetics
Pharmacology
Growth factor receptor
Receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations